PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: K3 Capital upbeat; Morses sinks after warning

Tue, 21st Jun 2022 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

K3 Capital Group PLC, up 10% at 258.36 pence, 12-month range 205.00p-380.00p. The professional advisory services firm says its annual results are likely to exceed market expectations. K3 says for the year ended May 31, revenue is expected to grow by around 43% to GBP77.5 million, from GBP47.2 million the year before. Adjusted earnings before interest, tax, depreciation and amortisation are expected to be 24% higher at GBP19.5 million from GBP15.7 million. The figures exceed market expectations, which according to Numis sit at GBP63.5 million for revenue and GBP18.2 million in Ebitda.

----------

Oxford Biodynamics PLC, up 8.0% at 17.55p, 12-month range 15.50p-62.80p. Shares in biotech firm move off 12-month lows after its checkpoint inhibitor response test becomes available in the UK. The EpiSwitch CiRT blood test predicts a patient's likely response to immune checkpoint inhibitor therapies, with high levels of sensitivity, specificity, accuracy and negative predictive value across 15 cancer indications where ICI treatments are approved. The test is now available to private physicians in the UK online. Oxford says the appeal of the test for the UK's National Health Service, given the high rates of inefficacy of ICI treatments, and their high costs.

----------

Midatech Pharma PLC, up 7.8% at 9.43p, 12-month range 8.16p-38.00p. The biotechnology company receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.

----------

AIM - LOSERS

----------

Morses Club PLC, down 24% at 7.91p, 12-month range 4.50p-95.00p. The doorstep lender warns that an increase in complaints could badly affect its trading performance for the first half of its financial year. Morses says that its home collected credit division has seen a rise in complaints submitted by claims management firms, leading to claim volumes returning to the level seen in February. Should this level be sustained, Morses expects the cost of the complaints could hurt its trading performance for the six months ending August 31.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Jul 2020 16:04

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
21 Jul 2020 16:40

Midatech Surges As It Lands Q-Sphera Pact With Unnamed Pharma Firm

Midatech Surges As It Lands Q-Sphera Pact With Unnamed Pharma Firm

Read more
21 Jul 2020 08:29

Midatech shares skyrocket as it enters new research collaboration

(Sharecast News) - Drug delivery technology company Midatech Pharma has entered into a research collaboration for the 'Q-Sphera' platform, it announced on Tuesday, with an unnamed European affiliate of a global pharmaceutical company.

Read more
16 Jun 2020 15:32

Revenues fall amid 'extremely difficult period' at Midatech

(Sharecast News) - Drug delivery technology company Midatech Pharma reported a fall in total gross revenue to £0.7m in its final results on Tuesday, from £1.9m year-on-year.

Read more
16 Jun 2020 12:07

Midatech Pharma Loss Narrows As Administrative, Research Costs Shrink

Midatech Pharma Loss Narrows As Administrative, Research Costs Shrink

Read more
8 Jun 2020 14:41

UK TRADING UPDATE SUMMARY: BlueRock Nets USD700,000 From Diamond Sales

UK TRADING UPDATE SUMMARY: BlueRock Nets USD700,000 From Diamond Sales

Read more
21 May 2020 15:54

Midatech raises $2.6m through offering and private placing

(Sharecast News) - Biotechnology company Midatech Pharma announced the closing of its registered direct offering of 1,818,182 American depositary shares (ADS), each representing five of its ordinary shares, at a price of $1.65 per ADS on Thursday.

Read more
18 May 2020 15:38

Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million

Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million

Read more
18 May 2020 11:04

Midatech Pharma To Report Narrowed Loss For 2019 On Lower Expenses

Midatech Pharma To Report Narrowed Loss For 2019 On Lower Expenses

Read more
13 May 2020 06:46

China Medical System Gives Up Right To Appoint Midatech Director

China Medical System Gives Up Right To Appoint Midatech Director

Read more
1 May 2020 14:12

Midatech Pharma Comments On Sudden Stock Price Rise

Midatech Pharma Comments On Sudden Stock Price Rise

Read more
1 May 2020 11:17

Midatech sees no reason for share surge

(Sharecast News) - Midatech Pharma said it knew of no reason for a surge in its share price on Friday morning.

Read more
20 Apr 2020 12:42

No Offers So Far For Midatech Pharma; Evaluating All Options

No Offers So Far For Midatech Pharma; Evaluating All Options

Read more
2 Mar 2020 19:44

Midatech Pharma Shareholders Approve Share Consolidation

Midatech Pharma Shareholders Approve Share Consolidation

Read more
2 Mar 2020 11:08

Midatech Pharma Initiates Study For MTX110 Drug For Brain Tumours

Midatech Pharma Initiates Study For MTX110 Drug For Brain Tumours

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.